Chevallier B, Asselain B, Kunlin A, Veyret C, Bastit P
Bull Cancer. 1986;73(2):139-47.
Between January 1977 and December 1982, 66 consecutive patients have been treated for unilateral, rapidly progressing, non metastatic breast cancer. They were divided into three groups: Group A (n = 10): tumor whom volume had increased during the 2 months before diagnosis; Group B (n = 30): inflammatory signs (erythema, skin oedema, elevated local temperature) involving less than one half of the breast; Group C (n = 26): inflammatory signs involving more than one half of the breast. All patients where managed similarly: 3 to 4 courses of chemotherapy (CMF: n = 24; AVCF: n = 42), then loco regional irradiation therapy with cobalt 60, followed by maintenance chemotherapy, only if the first chemotherapy had proved effective (CMF: n = 13; AVCF: n = 27). Nine patients with residual tumor after radiotherapy underwent mastectomy with axillary dissection. The actuarial 5 years survival for the whole group is 29%, and respectively 49%, 38% and 9% for the groups A, B and C. The median disease free intervals are 43, 29 and 12 months respectively. Fifteen prognostic factors likely to influence overall survival or disease free survival were evaluated. With univariate analysis, 8 factors were found to be of individual prognostic value: extent of initial erythema, erythema present after initial chemotherapy, erythema present after radiotherapy, non menopaused status, tumor diameter greater than 10 cms, residual breast tumor (clinical or radiographic) after maintenance chemotherapy, supra clavicular adenopathy (N3). Age at the diagnosis, type of chemotherapy, or performance of a radical mastectomy did not influence the prognosis. Multivariate analysis using the Cox-model isolated 3 factors of bad prognosis: erythema involving the whole breast at initial diagnosis, erythema present at the end of initial chemotherapy, N3.
1977年1月至1982年12月期间,连续66例单侧、快速进展、非转移性乳腺癌患者接受了治疗。他们被分为三组:A组(n = 10):肿瘤体积在诊断前2个月内增大;B组(n = 30):炎症体征(红斑、皮肤水肿、局部温度升高)累及不到一半乳房;C组(n = 26):炎症体征累及超过一半乳房。所有患者的治疗方式相似:3至4个疗程的化疗(CMF方案:n = 24;AVCF方案:n = 42),然后用钴60进行局部区域放射治疗,只有在首次化疗证明有效时才进行维持化疗(CMF方案:n = 13;AVCF方案:n = 27)。9例放疗后有残留肿瘤的患者接受了乳房切除术及腋窝淋巴结清扫术。全组的5年精算生存率为29%,A、B、C组分别为49%、38%和9%。无病生存期的中位数分别为43、29和12个月。评估了15个可能影响总生存期或无病生存期的预后因素。单因素分析发现8个因素具有个体预后价值:初始红斑范围、初始化疗后出现的红斑、放疗后出现的红斑、未绝经状态、肿瘤直径大于10厘米、维持化疗后残留乳腺肿瘤(临床或影像学)、锁骨上淋巴结肿大(N3)。诊断时的年龄、化疗类型或根治性乳房切除术的实施情况不影响预后。使用Cox模型的多因素分析确定了3个预后不良因素:初始诊断时累及全乳房的红斑、初始化疗结束时出现的红斑、N3。